Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"?

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 8, 2014, Pages 555-561

  Taylor, Clive R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; REAGENT; TUMOR MARKER;

COMPANION DIAGNOSTICS; CONTROL SYSTEM; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN SITU PROTEOMICS; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; NONHUMAN; PREDICTIVE VALUE; PROTEOMICS; REFERENCE VALUE; REVIEW; STAINING; STANDARDIZATION; TISSUE CHARACTERIZATION; DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; TRENDS; UNITED STATES;

BIOLOGICAL MARKERS; DIAGNOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE OF TESTS; PROTEOMICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84912567600     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000126     Document Type: Review

References (33)

1. Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008; 44:946-953.
2. Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Rev Drug Discov. 2011;10:735-748.
3. Pharmacogenomics Reporter. Draft of Hatch IVD bill-US Federal Legislation. 2011. Available at: http://www.genomeweb.com/dxpgx/ latest-draft-hatch-ivd-bill-contains-new-regulatory-proposals-pricingreforms- un. Accessed May 9, 2014.
4. FDA US Food and Drug Administration. Medical Devices. Classify Your Medical Device. [Code of Federal Regulations][Title 21, Volume 8][Revised as of April 1, 2012][CITE: 21CFR864.1860] [CITE: 21CFR864.1860]. Available at: http://www.fda.gov/Medical Devices/DeviceRegulationandGuidance/Overview/ClassifyYourDevice/ default.htm. Accessed May 2, 2014.
5. Walcoff SD. Facilitating the next generation of precision medicine in oncology. Person Med Oncol. 2012;1:43-51. Available at: www. personalizedMedOnc.com.
6. Becker RL. CDRH; Biomarkers for Devices. Discussion of Forum Workshop: Evaluation of Biomarkers and Surrogate Endpoints of Chronic disease. Washington, DC. Available at: http://www.iom. edu/~/media/Files/Activity%20Files/Research/BiomarkersChronDisease/ 2010-JUN-21/Becker.pdf. Accessed June 22, 2010.
7. Taylor CR. Quantifiable internal reference standards for immunohistochemistry; the measurement of quantity by weight. Appl Immunohistochem Mol Morph. 2006;14:253-259.
8. Taylor CR, Levenson RM. Quantification of immunohistochemistry- issues concerning methods, utility and semiquantitative assessment. Histopathology. 2006;49:411-424.
9. HercepTestTM Product Package insert. Available at: http://www. dako.com/us/ar39/p101510/prod-products.htm?setCountry=true &purl=ar39/p101510/prod-products.htm?undefined&submit= Accept%20country46. Accessed May 6, 2014.
10. Gu J, Taylor CR. Practicing pathology in the era of big data and personalized medicine. Appl Immunohistochem Mol Morph. 2014; 22:1-9.
11. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318: 1108-1113.
12. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546-1558.
13. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502: 333-339.
14. Williams ES, Hegde M. Implementing genomic medicine in pathology. Adv Anat Pathol. 2013;20:238-244.
15. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854.
16. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032-3038.
17. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
18. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21:S8-S15.
19. Taylor CR. Focus on Biospecimens: the issue is the tissue. Observations on the "NCI-NIST fitness for purpose quality assessment and standards workshop". Appl Histochem Mol Morph. 2011;19:95-98.
20. Hewitt SM, Robinowitz M, Bogen SA, et al. Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays: Approved Guidelines. Vol. 31. 2nd ed. Wayne, PA: Clinical Lab Standards Institute; 2011;4.
21. Taylor CR, Becker KF. Liquid morphology: immunochemical analysis of proteins extracted from formalin fixed paraffin embedded tissues: combining proteomics with immunohistochemistry. Appl Immunohistochem Mol Morph. 2011;19:1-9.
22. Neumeister VM, Parisi F, England AM, et al. Models and techniques. A tissue quality index; an intrinsic control for measurement of effects of pre-analytic variables on FFPE tissue. Lab Invest. 2014;94:467-474.
23. NordiQC. Nordic Immunohistochemical Quality Control. Available at: http://www.nordiqc.org. Accessed May 14, 2014.
24. UKNEQAS. United Kingdom National External Quality Assessment Service. Available at: http://www.ukneqas.org.uk. Accessed May 14, 2014.
25. Cartun RW. Negative reagent controls in diagnostic immunohistochemistry: do we need them? An evidence-based recommendation for laboratories throughout the world. Applied Immunohistochem Mol Morph. 2014;22:159-161.
26. Torlakovic EE, Francis G, Garratt J, et al. Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Committee. Appl Immunohistochem Mol Morph. 2014;22:241-252.
27. Torlakovic EE, Francis G, Garratt J, et al. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Committee. Appl Immunohistochem Mol Morph. 2014;22:241-252.
28. Taylor CR, Cote RJ. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist. 3rd ed. Philadelphia: Elsevier, Saunders; 2005.
29. Taylor CR, Shi SR, Barr N, et al. Techniques of immunohistochemistry: principles, pitfalls and standardization. Chapter 1. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia: Elsevier; 2006.
30. Taylor CR. From microscopy to whole slide digital images: a century and a half of image analysis. Appl Histochem Mol Morph. 2011;19:491-493.
31. Welsh AW,Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol. 2011;29:2978-2984.
32. PerkinElmer. Opal Multiplex Tissue Staining. 2014. Available at: http://www.perkinelmer.com/catalog/category/id/opal-multiplextissue- staining. Accessed May 2, 2014.
33. Gerdes MJ, Sevinsky CJ, Sood A, et al. Highly multiplexed singlecell analysis of formalin-fixed paraffin-embedded cancer tissue. PNAS. 2013. doi: 10.1073/pnas.1300136110. Available at: http:// www.pnas.org/content/early/2013/06/27/1300136110.